High RNF5 expression is associated with poor AML prognosis, and inhibition of RNF5 decreases AML growth and sensitizes it to histone deacetylase (HDAC) inhibitors in preclinical models [142]. The gene discussed is HDAC9; the disease is acute myeloid leukemia.